[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,44,73,97,121,159,190,215,240,267,291,321,348,375,400,425,458,487,515,538,562,591,614,642,662],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100054244","phase-4-the-ed95-of-ciprofol-for-laryngeal-mask-airway-insertion-with-fentanyl-in-children-a-biased-coin-dose-finding-trial-100054244",false,"NCT07697404","The ED95 of Ciprofol for Laryngeal Mask Airway Insertion With Fentanyl in Children: A Biased-Coin Dose-Finding Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status I or II\n* Aged 1 to 12 years\n* Scheduled for elective surgery requiring general anesthesia with laryngeal mask airway (LMA) insertion (e.g., ophthalmic surgery, skin lesion excision, minor abdominal or urological procedures, with expected surgical duration ≤ 2 hours)\n* Written informed consent obtained from parents or legal guardians\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to ciprofol, fentanyl, or any study-related drugs\n* Intellectual disability, cognitive-affective disorders, psychiatric or neurological diseases\n* Inability to cooperate with peripheral intravenous cannulation\n* History of reactive airway disease or suspected difficult airway\n* Body mass index (BMI) ≥ 30 kg\u002Fm² or ≤ 15 kg\u002Fm²\n* History of sedative medication use\n* Inability to understand the study protocol or participation in another clinical trial within the past 30 days","ALL","1 Year","12 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Ciprofol is a novel intravenous anesthetic with a pharmacological profile similar to propofol but with a lower incidence of injection pain, hypotension, and respiratory depression. For pediatric day-case surgeries, laryngeal mask airway (LMA) insertion without neuromuscular blockers is increasingly preferred. While opioids are often combined with hypnotics to optimize insertion conditions, the optimal bolus dose of ciprofol when co-administered with a standard dose of fentanyl for LMA insertion in children remains unknown. This study aims to determine the 95% effective dose (ED95) of a single intravenous bolus of ciprofol, combined with a fixed dose of fentanyl (1 μg\u002Fkg), for successful LMA insertion in children aged 1-12 years during general anesthesia induction.",[27,28,29,30],"Pediatric","Anesthesia Induction","Ciprofol","Laryngeal Mask Airway","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2026-06-15",{"date":39,"type":21},"2028-12-01",{"name":41,"class":42},"Huazhong University of Science and Technology","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100641641","use-of-the-single-port-robotic-system-in-pediatric-surgery-100641641","NCT07660497","Use of the Single Port Robotic System in Pediatric Surgery","SPCHIRPED","Inclusion Criteria:\n\n* Aged between 10 and 17 inclusive for the first five and between 1 and 17 for the next five\n* Parents or guardians affiliated with or entitled to social security\n* Patient and legal representative of the patient who has received informed information about the study and has signed the consent form for the child's participation in the study.\n* Patients seen in paediatric surgery consultations at Saint-Etienne University Hospital\n* Patient requiring abdominal surgery such as pyeloplasty, vesicoureteral reflux or gastro-oesophageal reflux\n\nExclusion Criteria:\n\n* History of haemorrhagic disease\n* History of multiple abdominal surgeries (as intraperitoneal adhesions can make surgical access difficult)\n* Pregnant adolescents\n* Patients with electronic implants (e.g. pacemakers).\n* Parents or guardians under guardianship or trusteeship.","17 Years",{"count":53,"type":21},10,[55],"NA","Open surgery (laparotomy) has long been the gold standard for pediatric surgery. The development of laparoscopy in the 1980s reduced post-operative pain. Since the 2000s, robotic surgery has been on the rise. The most commonly used robotic system is the Xi robotic system (Intuitive Surgical), which allows instruments to be inserted through three or four trocars and replicates the movements of the surgeon's hands as they sit at a control console a few meters away from the patient.The Single Port (SP) robotic system is a new development in this technology. It allows the same procedures to be performed using a single trocar instead of four. CE marking was obtained in 2024 for abdominal surgery, but without provision for use in children. The pediatric surgery team at Saint-Etienne University Hospital has been performing robotic surgery using the Xi (Intuitive) system since January 2020. Between January 2020 and April 2025, 150 patients underwent surgery, including 49 pyeloplasties, 42 ureterovesical reimplantations, and 23 gastroesophageal reflux treatments. No conversions were necessary, and there were no complications related to the use of the robotic system. The Saint-Etienne University Hospital was the first institution in France to acquire the SP robotic system.",[58,27,59],"Robotic System","Surgery in Children",[61,62,63],"Single Port Robotic System","Pediatric surgery","Access Port","2026-06-16",{"date":66,"type":35},"2026-06-22",{"date":68,"type":35},"2025-11-14",{"date":70,"type":21},"2026-12-15",{"name":72,"class":42},"Centre Hospitalier Universitaire de Saint Etienne",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100617942","quantifying-motor-network-dynamics-to-predict-and-enhance-outcomes-in-pediatric-dystonia-100617942","NCT07325175","Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia","Inclusion Criteria:\n\n* For dystonia subjects:\n* Dx of dystonia (with and without DBS)\n* willingness and ability to complete study protocols.\n* For Typically Developing Controls:\n* normal developmental milestones\n* absence of any neuropsychiatric disorder\n* no significant medical condition.\n\nExclusion Criteria:\n\n* history of epilepsy\n* presence of implanted medical devices (except DBS in dystonia subjects)\n* lack of cognitive or physical ability to complete study protocol.",true,"6 Years","21 Years",{"count":83,"type":21},75,[55],"The goal of this study is to understand the development and progression of childhood dystonia, a movement disorder, in children. The main questions it aims to answer are:\n\nHow does the activity of the neural network evolve in children with dystonia in the context of motor development? What are the effects of chronic and active stimulation on cortical and subcortical motor network function in children with deep brain stimulation (DBS)?\n\nParticipants will:\n\n* Undergo noninvasive electrophysiological measurements (EEG, EMG) to quantify neural network activity. They will be tested at rest and during a simple motor reaction task.\n* Children with DBS will be assessed in the on and off DBS state to assess effects of chronic and active changes in motor network function.",[87,27,88,89],"Dystonia","Deep Brain Stimulation","Motor Development",{"date":64,"type":35},{"date":92,"type":35},"2024-01-01",{"date":94,"type":21},"2029-12-31",{"name":96,"class":42},"Children's Hospital Medical Center, Cincinnati",{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":16,"minAge":80,"maxAge":18,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":43},"100638878","external-oblique-intercostal-plane-block-versus-erector-spinae-plane-block-in-paediatric-upper-abdominal-surgeries-100638878","NCT07617545","External Oblique Intercostal Plane Block Versus Erector Spinae Plane Block in Paediatric Upper Abdominal Surgeries","Ultrasound Guided External Oblique Intercostal Plane Block Versus Erector Spinae Plane Block in Paediatric Upper Abdominal Surgeries","Inclusion Criteria:\n\n* Children aged between 6 and 12 years of both sex.\n* Patients with the American Society of Anesthesiologists (ASA) physical status I\u002FII.\n* Patients undergoing upper abdominal surgeries involving upper abdominal incisions.\n\nExclusion Criteria:\n\n* Guardian refusal.\n* Allergy to local anesthetics.\n* Surgical procedures exceeding 3 hours.\n* Infection at the area planned for the block injection.\n* Prolonged opioid medication.\n* Patients preoperatively medicated by Beta blockers",{"count":105,"type":21},40,[55],"This study aims to compare between ultrasound guided external oblique intercostal plane block and ultrasound guided erector spinae plane block in paediatric upper abdominal surgeries.",[109,110,27,111],"External Oblique Intercostal Plane Block","Erector Spinae Plane Block","Upper Abdominal Surgeries","2026-05-24",{"date":114,"type":35},"2026-06-01",{"date":116,"type":35},"2025-05-01",{"date":118,"type":21},"2026-10-01",{"name":120,"class":42},"Alexandria University",{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":134,"conditions":135,"keywords":142,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100625550","phase-2-intratumoral-dnx-2401-for-high-grade-pediatric-brain-tumors-100625550","NCT07424092","Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors","Intratumoral DNX-2401 Administration for Recurrent and Refractory High Grade Brain Tumors in Pediatric and Young Adult Patients","PED-DNX2401","Inclusion Criteria:\n\n* The participant or participant's parents or legally acceptable representatives (if applicable) provides written informed consent for the trial and the pediatric participant provides writ-ten assent, where applicable, based on age and country requirements.\n* Patients with recurrent or refractory high grade malignant brain tumors (high grade glioma, embryonal CNS tumors \\[medulloblastomas, ATRT, EMTR, pineoblastoma\\], and ependymomas) diagnosis based on initial histopathological diagnosis and further clinical and radiological fol-low-up, in whom gross total resection is not feasible, and with a life expectancy of at least 16 weeks at the time of consent.\n* Recurrences within the radiation field will be considered if there is confirmed growth of the lesion in two consecutive MRI or if they occur at least 12 weeks after completion of ra-diation therapy, or if there is clear histopathological confirmation of tumor recurrence.\n* Male and female participants age ≥ 1 years and ≤ 25 years.\n* A single measurable lesion longer than 10 mm in two perpendicular diameters, considered by the investigator to be accessible for safe stereotactic biopsy and virus injection.\n* Lansky Performance Status (LPS) ≥ 60 for participants \\\u003C 16 years, or Karnofsky Performance Status (KPS) ≥ 60 for participants ≥ 16 years.\n* No other chemotherapy or immunotherapy in the 4 weeks before inclusion.\n* Steroids: free off or requiring decreasing or stable corticosteroid dose (≥ 0.05 mg\u002Fkg dexa-methasone daily, or equivalent for other steroids) in the 2 weeks before DNX-2401 admin-istration.\n* Radiation: no craniospinal irradiation, total body irradiation nor focal irradiation in the 6 weeks before inclusion.\n* Autologous Stem Cell Transplantation: patients must be ≥ 3 months post-transplant prior to entry of the study.\n* Patients must be fully recovered from all acute treatment related toxicities of all prior therapies.\n* Laboratory test: adequate hematological (platelets ≥ 100x10e9\u002FL, neutrophils ≥ 1.0x10e9\u002FL, hemoglobin ≥ 5,6 mmol\u002FL), renal function (creatinine \\\u003C1.5 times ULN) and liver function (≤3 times ULN) values.\n* Negative pregnancy test for female participants of child-bearing potential, where child-bearing potential is defined as a fertile female who is pubertal or post-pubertal and not permanently sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy).\n* Female participants of child-bearing potential, who are sexually active, agree to use ac-ceptable birth control starting at informed consent and continuing for at least 120 days af-ter DNX-2401 administration. Male participants agree to use acceptable birth control start-ing at informed consent and continuing for at least 90 days after DNX-2401 administration.\n\nExclusion Criteria:\n\n* Any medical or psychological condition or disease that might interfere with the subject's ability to participate or give informed consent (if older than 16 years).\n* Spinal location, or lesions considered risky for stereotactic injection of virus or that might favor entrance of the virus in the ventricular system.\n* Any treatment outside the allowable guidelines outlined in the inclusion criteria.\n* Severe acute infection or intercurrent medical condition including, but not limited to se-vere renal, hepatic, heart or bone marrow failure that based on investigator discretion do not permit inclusion in the study.\n* Subjects with immunodeficiency or autoimmune conditions, active hepatitis or known HIV. No testing for Hepatitis B, Hepatitis C and HIV is required unless mandated by local health authority.\n* Subjects with another primary malignancy.\n* Prior history of encephalitis, multiple sclerosis or other CNS infections or primary CNS dis-ease that would interfere with evaluation.\n* Li Fraumeni Syndrome or a known germ line deficit in the retinoblastoma gene or its relat-ed pathways.\n* Concurrent therapy with any antiviral drug or any immunosuppressive drug (except ster-oids).\n* Life or life-attenuated vaccinations within 30 days prior to DNX-2401 administration and while participating in the study. Killed vaccines are permitted.\n* Prior participant in experimental viral therapy.\n* Inability to undergo MRI scans for any reason.\n* Pregnancy or breastfeeding.","25 Years",{"count":131,"type":21},39,[133],"PHASE2","The goal of this clinical trial is to learn if intratumoral administration of DNX-2401 works to treat recurrent and refractory high grade brain tumors in children and young adults. It will also learn about the safety of DNX-2401.\n\nThe main questions it aims to answer are:\n\n* Does a single intratumoral administration of DNX-2401 elicit tumor response and improve survival?\n* Is a single intratumoral administration of DNX-2401 safe and well tolerated?\n\nParticipants will:\n\n* Undergo surgery for tumor biopsy followed by a single intratumoral administration of DNX-2401\n* Visit the clinic periodically for checkups and tests",[136,137,138,139,140,27,141],"High Grade Glioma","Ependymoma","Embryonal Tumor of Brain","Recurrence","Refractory","Young Adult",[143,136,137,144,145,146,147,148],"High Grade Brain Tumors","Embryonal CNS Tumors","Recurrent or refractory","Pediatric and young adult patients","Oncolytic virus","DNX-2401","2026-05-21",{"date":151,"type":35},"2026-05-27",{"date":153,"type":35},"2026-05-12",{"date":155,"type":21},"2029-05",{"name":157,"class":42},"Clinica Universidad de Navarra, Universidad de Navarra",2,{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":43},"100633957","long-term-follow-up-of-pituitary-and-hypothalamic-dysfunction-in-children-who-have-suffered-moderate-to-severe-head-trauma-included-in-the-endoc-tc-cohort-100633957","NCT07533435","Long-term Follow-up of Pituitary and Hypothalamic Dysfunction in Children Who Have Suffered Moderate to Severe Head Trauma Included in the ENDOC TC Cohort","ENDOC TC 2","Inclusion Criteria:\n\n* Consent of the child if under 18 years of age and no objection from both parents, or no objection from the adult patient\n* Patients included in the Princeps Endoc TC study in Lyon\n\n  * Patients who have suffered a traumatic brain injury\n  * Children aged 2 months to 16 years inclusive\n  * Admitted to pediatric intensive care\n  * Initial Glasgow Coma Scale score between 3 and 12, regardless of the mechanism of head injury\n  * Informed consent signed by parents\n\nExclusion Criteria:\n\n* Patient deceased since the end of Endoc TC study",{"count":167,"type":21},90,"OBSERVATIONAL","The annual incidence of traumatic brain injury (TBI), all causes combined, varies between 180 and 300 per 100,000. TBI increases the risk of death or serious sequelae by a factor of 8.\n\nStudies conducted in adults have shown an anterior pituitary deficit in 28% to 68% of patients with TBI. The variability of these studies does not currently allow for standardization of the management of these children in either the acute or late phases.\n\nSeveral studies, including a Lyon-based study called Endoc TC (Ref. Clinical Trials: NCT01250132), have aimed to investigate the association between anterior pituitary deficits in the acute phase and those identified a few months after the trauma.\n\nSince then, few studies have been conducted more than five years after the trauma to study its pituitary consequences.\n\nTo date, the investigators have sought to study the long-term prevalence of pituitary and hypothalamic dysfunction in patients who suffered moderate to severe head trauma during childhood, specifically patients included in the initial Endoc TC study in Lyon.\n\nTo this end, the main objective is to determine the current height of these patients and whether there are any associated growth delays or other clinical signs that may suggest the presence of a pituitary or hypothalamic hormone deficiency.\n\nThis study consists of a telephone questionnaire lasting approximately 15 minutes, with participants from Lyon who took part in ENDOC TC study, designed to determine the growth of these patients and the presence or absence of symptoms that may be related to post-traumatic damage to the hypothalamic-pituitary system linked to head trauma.",[171,172,27,173],"Craniocerebral Trauma","Hypothalamic-pituitary Disorders","Endocrinology",[175,176,177,178,179],"Traumatic brain injury","Anterior pituitary deficits","Growth delaus","Pituitary or hypothalamic hormone deficiency","Initial Endoc TC study (Ref. Clinical Trials : NCT01250132)","NOT_YET_RECRUITING","2026-05-20",{"date":183,"type":35},"2026-05-22",{"date":185,"type":21},"2026-04-22",{"date":187,"type":21},"2026-09-30",{"name":189,"class":42},"Hospices Civils de Lyon",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":158},"100304425","phase-2-efficacy-of-rapamycin-in-the-treatment-of-cervico-facial-lymphatic-malformations-100304425","NCT03243019","Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations","Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis","RAPAMALYMPH","Inclusion Criteria:\n\n* Patient from 0 to 18 years of age, presenting with poly-cystic suprahyoid or mediastinal lymphatic.\n* with chronic pain or functional respiratory or swallowing impairment with a CDS score \\\u003C 8\n* Curative treatment is not possible or associated with a high risk of morbidity ,mortality and functional and cosmetic impairment\n* Karnofsky Score (\\> 10 years of age) or Lansky score (≤10 years of age) \\> 50%\n* Biology\n\n  * Neutrophils count≥1.0 x 109\u002FL\n  * Platelets count ≥ 100 x 109\u002FL\n  * Hemoglobin ≥ 8 g\u002FdL\n  * Bilirubin ≤ 1,5 ULN\n  * Transaminases \\\u003C 2,5 ULN\n  * Serum albumin ≥ 2 g\u002FdL.\n  * LDL cholesterol \\\u003C160 mg\u002FdL\n  * Triglycerides \\\u003C 150 mg\u002FdL\n* Negative test of pregnancy if relevant\n* Social security affiliation\n* At least 2 months after a previous procedure on the malformation\n\nExclusion Criteria:\n\n* Non-respect of inclusion criteria\n* Other immunosuppressive therapy or long-term general corticosteroid therapy without a 28-day washout period\n* renal failure\n* Liver failure\n* Digestive disease leading to rapamycin malabsorption\n* uncontrolled or severe infectious disease\n* Patients requiring treatment interfering with CYP3A4 isoenzyme (rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin) or inhibiting CYP3A4 isoenzyme's activity (ketoconazole, voriconazole, itraconazole, telithromycin, clarithromycin, Diltiazem, Verapamil, nicardipine, clotrimazole, fluconazole , troleandomycin, bromocriptine, cimetidine, danazol, protease inhibitors) -patients requiring treatment by cisapride and metoclopramide\n* Concomitant administration of mTOR inhibitor\n* Peanuts or soya allergy\n* Impossibility to receive informed consent\n* Absence of social security affiliation\n* refusal to sign consent\n* Ongoing pregnancy or breastfeeding\n* refusal to participate","18 Years",{"count":200,"type":21},28,[133],"To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in pediatric patients. Rapamycin is administered oral for a 6 month period.\n\nThe success rate is determined by volume reduction superior to 1\u002F5e of the initial volume measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.",[204,27],"Lymphatic Malformation",[206,207],"cervico-facial","rapamycin",{"date":183,"type":35},{"date":210,"type":35},"2018-06-25",{"date":212,"type":21},"2027-02",{"name":214,"class":42},"University Hospital, Lille",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":16,"minAge":223,"maxAge":18,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":238,"locationsCount":43},"100636178","laryngeal-mask-airways-are-supraglottic-devices-used-to-maintain-airway-patency-during-anesthesia-and-in-difficult-airways-iv-dexmedetomidine-improves-lma-insertion-success-and-decreases-coughing-while-iv-lidocaine-decreases-postoperative-cough-100636178","NCT07562308","Laryngeal Mask Airways Are Supraglottic Devices Used to Maintain Airway Patency During Anesthesia and in Difficult Airways. IV Dexmedetomidine Improves LMA Insertion Success and Decreases Coughing, While IV Lidocaine Decreases Postoperative Cough.","Intravenous Dexmedetomidine Vs. Lidocaine for Laryngeal Mask Insertion Conditions In Pediatric Patients Undergoing Elective Surgeries, A Randomized Controlled Trial.","DEX LMA","Inclusion Criteria:\n\n* Parental\u002Fguardian consent.\n* Age 2-12 years\n* ASA physical status I-II.\n* Elective surgery requiring LMA (duration \\\u003C2 hours).\n\nExclusion Criteria:\n\n* Known airway anomalies (e.g., tonsillar hypertrophy, cleft palate).\n* Cardiovascular disease (bradycardia, arrhythmias).\n* Allergy to study drugs.\n* BMI \\>95th percentile.","2 Years",{"count":225,"type":21},60,[55],"Laryngeal Mask Airways Are Supraglottic Devices Used to Maintain Airway Patency During Anesthesia and in Difficult Airways. LMA may help in reducing postoperative pulmonary complications. IV Dexmedetomidine Improves LMA Insertion Success and Decreases trials number, While IV Lidocaine Decreases Postoperative Cough. This is a randomized interventional trial comparing both drugs. IV DEX will be compared vs IV lidocaine regarding the feasibility of insertion, number of trials, incidence of cough, postoperative pulmonary complications and hemodynamic profile.",[27,229,230],"Elective","Surgery in Early Childhood",[232],"Dexmedetomidine, Lidocaine, LMA, Pediatrics, Elective","2026-05-08",{"date":153,"type":35},{"date":236,"type":21},"2026-05-01",{"date":187,"type":21},{"name":239,"class":42},"Assiut University",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":79,"sex":16,"minAge":17,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":4},"100625769","comparison-of-erector-spinae-plane-block-and-caudal-block-in-pediatric-patients-aged-1-to-8-years-undergoing-lower-abdominal-surgery-100625769","NCT07426939","Comparison of Erector Spinae Plane Block and Caudal Block in Pediatric Patients Aged 1 to 8 Years Undergoing Lower Abdominal Surgery","Inclusion Criteria:\n\nChildren aged 1 to 8 years\n\nScheduled for elective lower abdominal surgery\n\nAmerican Society of Anesthesiologists (ASA) physical status I-II\n\nWritten informed consent obtained from parent(s) or legal guardian(s)\n\nExclusion Criteria:\n\nPresence of anatomical abnormalities\n\nCoagulation disorders\n\nInfection at the site of block application\n\nSevere cardiovascular, neurological, respiratory, or metabolic disease\n\nKnown allergy to study medications\n\nFailed regional block\n\nBilateral surgery or additional surgical procedures involving different surgical sites\n\nRefusal of parent(s) or legal guardian(s) to provide consent","8 Years",{"count":248,"type":21},78,[55],"In routine pediatric surgical practice, lower abdominal surgeries are commonly performed. Inadequate control of postoperative pain can hinder functional recovery and may lead to negative behavioral changes as well as parental dissatisfaction. Regional anesthesia techniques are widely recommended for pain management in pediatric surgery, as they reduce the need for parenteral opioids and improve the effectiveness of postoperative pain control, patient comfort, and parental satisfaction.\n\nVarious nerve block techniques have been developed to enhance postoperative analgesia and facilitate recovery in pediatric patients. However, there is still no consensus regarding the most effective regional anesthesia strategy for pediatric surgical procedures.\n\nAmong regional anesthesia techniques used for pain management in children undergoing lower abdominal surgery, caudal block remains the most commonly applied method. The introduction of real-time ultrasound guidance has improved the reliability and safety of caudal blocks. Nevertheless, a major limitation of this technique is its relatively short duration of action following a single injection, even when long-acting local anesthetics or adjuvant agents are used. Consequently, several fascial plane blocks, such as the quadratus lumborum block, transversus abdominis plane block, and rectus sheath block, have been proposed as alternative approaches for postoperative analgesia in children.\n\nThe erector spinae plane block is a regional anesthesia technique that has been applied at thoracic, lumbar, cervical, and sacral levels for both acute and chronic pain management. By providing blockade of both somatic and visceral pain pathways, it has demonstrated effective postoperative analgesic properties in a variety of thoracic and abdominal surgical procedures. The technique involves the injection of a local anesthetic into the interfascial plane between the erector spinae muscle and the transverse process, allowing longitudinal spread of the anesthetic across multiple spinal levels.\n\nWith a growing body of evidence supporting its feasibility and effectiveness, the erector spinae plane block has gained increasing attention in pediatric anesthesia practice.\n\nThe aim of this study is to evaluate and compare the analgesic efficacy and safety of ultrasound-guided erector spinae plane block and caudal block in pediatric patients undergoing unilateral lower abdominal surgery under general anesthesia. The primary objective is to compare postoperative pain levels between the two techniques using the FLACC score, which assesses facial expression, leg position, activity, crying, and consolability. Secondary objectives include the evaluation of intraoperative heart rate, blood pressure, and oxygen saturation, block application times, parental satisfaction, and the incidence of postoperative side effects.",[252,110,27],"Caudal Epidural Anesthesia",[254,255,256,257],"espb","caudal block","pediatric","erector spinae plane block","2026-05-06",{"date":260,"type":35},"2026-05-11",{"date":262,"type":21},"2026-04-15",{"date":264,"type":21},"2026-09-01",{"name":266,"class":42},"Ankara City Hospital Bilkent",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":16,"minAge":223,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":43},"100599777","the-effectiveness-of-dexmedetomidine-as-an-adjuvant-for-bupivacaine-caudal-block-in-pediatric-open-appendectomy-under-general-anesthesia-100599777","NCT07088900","The Effectiveness of Dexmedetomidine as an Adjuvant for Bupivacaine Caudal Block in Pediatric Open Appendectomy Under General Anesthesia","inclusion criteria:\n\n* ASA (American Society of Anesthesiologists) physical status I or II.\n* Legal guardian provides written informed consent. Exclusion Criteria\n* Refusal of participation by the legal guardian.\n* Known allergy or hypersensitivity to local anesthetics or dexmedetomidine.\n* Coagulation disorder or receiving anticoagulant therapy.\n* Active infection at or near the injection site.\n* Significant anatomical abnormalities of the lumbosacral spine.\n* Pre-existing neurological disorders, psychiatric disorders, or a history of convulsions.\n* Anticipated surgery time of more than 2.5 hours.\n* Patients with severe asthma or active wheezing.","7 Years",{"count":225,"type":21},[55],"This study aims to evaluate if adding dexmedetomidine to bupivacaine in a caudal block can provide longer and better quality pain relief for children after open appendectomy surgery. The study will also assess the effect of this combination on the quality of recovery, including the incidence of emergence delirium, and its overall safety profile.",[278,27],"Appendectomy",[280,281,282],"caudal","dexmedetomidine","open appendectomy","2026-04-30",{"date":258,"type":35},{"date":286,"type":35},"2025-08-01",{"date":288,"type":21},"2026-07-30",{"name":290,"class":42},"Ain Shams University",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":79,"sex":16,"minAge":298,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":22,"phases":302,"briefSummary":303,"conditions":304,"keywords":306,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":318,"locationsCount":320},"100504750","comparing-a-team-based-approach-to-standard-well-child-visits-to-improve-preventive-care-services-100504750","NCT05852392","Comparing a Team-Based Approach to Standard Well-Child Visits To Improve Preventive Care Services","Parent-focused Redesign for Encounters, Newborns to Toddlers (PARENT) Trial: Comparing Two Models of Well-Child Care for Black Families","Inclusion Criteria:\n\nParticipants are not individually recruited or enrolled; rather we collect de-identified Electronic Health Record (EHR) and administrative data on all children in the practices who:\n\n1. are age ≥9 and ≤15 months on day of data collection,\n2. have ≥1 visit at the practice in previous 9 months\n3. are insured by Partners for Kids, the Accountable Care Organization (ACO) for NCH-PCN\n\nExclusion Criteria:\n\n* N\u002FA","9 Months","15 Months",{"count":301,"type":21},12,[55],"Parent-focused Redesign for Encounters, Newborns to Toddlers (PARENT) is a team-based approach to care that utilizes a community health worker in a health educator role (\"Parent's Coach\") to provide many of the Well-Child Care (WCC) services that children and families should receive, addresses specific needs faced by families in low-income communities, and decreases reliance on the clinician as the primary provider of WCC services. The model was developed in partnership with clinics and parents in low-income communities and previously tested among largely Latino, Medicaid-insured populations. The aims of this study are to (1) Adapt the PARENT intervention to meet the needs of a diverse, largely Black population of underserved families, (2) Determine the effect of adapted PARENT on receipt of nationally recommended preventive care services, emergency department utilization, and parent experiences of care, (3) Determine whether the effectiveness of adapted PARENT differs by family-level factors, (4) Explore parents' experiences in receiving adapted PARENT, (5) Examine the economic impact of adapted PARENT from the parent stakeholder perspective, (6) Examine the economic impact of adapted PARENT from the pediatric provider and clinic stakeholder perspective, and (7) Examine the economic impact of adapted PARENT on healthcare utilization, from the perspectives of parents and families.\n\nThis study will evaluate the effectiveness of the adapted PARENT model as compared to traditional guideline-based WCC and assess the patient-centered economic outcomes of the adapted PARENT model.",[27,305],"Well Child Care",[307,305,308,309,310,311,312],"Community Health Workers","Black Children","Black Families","Preventive Care","Early Childhood","Patient-centered economic outcomes",{"date":314,"type":35},"2026-05-07",{"date":316,"type":35},"2023-06-30",{"date":39,"type":21},{"name":319,"class":42},"Seattle Children's Hospital",3,{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":198,"enrollmentInfo":329,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":43},"100636349","efficacy-and-safety-of-a-combined-dexmedetomidine-ketamine-sedation-regimen-for-pediatric-cardiac-catheterization-100636349","NCT07564531","Efficacy and Safety of a Combined Dexmedetomidine-Ketamine Sedation Regimen for Pediatric Cardiac Catheterization","Evaluation of the Efficacy and Safety of a Combined Dexmedetomidine-Ketamine Sedation Regimen for Pediatric Cardiac Catheterization at Vietnam National Children's Hospital","KETADEX","Inclusion Criteria:\n\n* Patients under 18 years of age.\n* Patients indicated for diagnostic or interventional cardiac catheterization.\n\nExclusion Criteria:\n\n* Patients with acute respiratory infections, chromosomal abnormalities, metabolic disorders, or other co-existing medical conditions.\n* Arrhythmias, second- or third-degree atrioventricular (AV) block; patients on mechanical ventilation or requiring vasopressors prior to the procedure.\n* Known history of allergy or hypersensitivity to dexmedetomidine, ketamine, propofol, midazolam, or sevoflurane.",{"count":330,"type":21},150,"The goal of this observational study is to learn if the spontaneous sedation regimen of dexmedetomidine-ketamine (KETADEX) has the comparable efficacy and safety in pediatric cardiac catheterization versus the traditional regimen. The main question it aims to answer is:\n\nIs the combined Dexmedetomidine-Ketamine spontaneous sedation regimen (KETADEX) non-inferior to the traditional general anesthesia regimen in terms of efficacy and safety?\n\nParticipants would received either KETADEX regimen or general anesthesia regimen. Research members then observe the catheterization procedure and answer the questionnaire about their efficacy and safety.",[333,27],"Cardiac Catheterization",[281,335,336,337,338],"ketamine","spontaneous sedation","general anesthesia","cardiac catheterization","2026-04-29",{"date":341,"type":35},"2026-05-04",{"date":343,"type":35},"2026-02-04",{"date":345,"type":21},"2026-12-30",{"name":347,"class":42},"National Children's Hospital, Vietnam",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":16,"minAge":273,"maxAge":51,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":364,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":371,"leadSponsor":373,"locationsCount":43},"100514681","level-up-adaptive-gaming-for-children-with-upper-limb-differences-100514681","NCT05981664","Level Up! Adaptive Gaming for Children With Upper Limb Differences","Inclusion Criteria:\n\n* between the age of 7 and 17 years\n* has a unilateral limb difference\n* limb difference may be from any cause (congenital difference, traumatic loss, etc.)\n* limb difference may be of any level (partial hand, wrist disarticulation, transradial, elbow disarticulation, transhumeral, shoulder disarticulation)\n* ability to communicate in English\n* cognitive ability to follow instructions\n* eligible participants will be included regardless of history of prosthesis use\n* lives locally (Winnipeg) or willing and able to travel to Rehabilitation Centre for Children for 2 appointments\n\nExclusion Criteria:\n\n* less than 7 or greater than 17 years of age\n* bilateral or no limb upper limb difference\n* inability to communicate in English\n* cognitive inability to follow instructions\n* unable or unwilling to attend 2 appointments at Rehabilitation Centre for Children",{"count":355,"type":21},20,[55],"The goal of this clinical trial is to test a new one-handed video game controller adapter to determine if it helps improve how video games are played and enjoyed in children with an upper limb difference on one side. The main questions it aims to answer are:\n\n* Is performance improved while playing video games with the adapter?\n* Is user satisfaction or enjoyment improved while playing video games with the adapter?\n\nParticipants will:\n\n* Answer questions about their limb difference and other demographics\n* Be interviewed about their current and past video game playing experiences\n* Learn how to use the adapter and have their performance with it evaluated\n* Take the adapter home to use for 1 week, and be asked to record their experiences\n* Have their performance with the adapter re-evaluated after a week of practice\n* Be interviewed about their experience with the adapter",[359,27,360,361,362,363],"Upper Limb Amputation at the Wrist","Upper Limb Amputation","Upper Limb Amputation at the Hand","Amniotic Band Syndrome","Upper Limb Amputation Below Elbow (Injury)",[256,365,366],"upper limb difference","one handed gaming","2026-04-28",{"date":369,"type":35},"2026-05-05",{"date":92,"type":35},{"date":372,"type":21},"2027-06",{"name":374,"class":42},"University of Manitoba",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":16,"minAge":382,"maxAge":273,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":392,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":398,"locationsCount":43},"100635814","effect-of-opioid-free-vs-opioid-based-anesthesia-on-postoperative-pain-and-emergence-agitation-in-children-undergoing-cleft-surgery-100635814","NCT07557576","Effect of Opioid-Free vs Opioid-Based Anesthesia on Postoperative Pain and Emergence Agitation in Children Undergoing Cleft Surgery","Comparison of Impact of Opioid and Non-Opioid Anesthesia on Pain and Agitation Levels in Children After Cleft Lip and Palate Surgery","Inclusion Criteria:\n\n* ASA physical status I-II\n* Body weight \\>5 kg\n* Age ≥3 months for cleft lip repair and ≥9 months for cleft palate repair\n* Hemoglobin \\>100 g\u002FL\n\nExclusion Criteria:\n\n* ASA physical status III-IV\n* Body weight \\\u003C5 kg\n* Age \\\u003C3 months for cleft lip repair or \\\u003C9 months for cleft palate repair\n* Hemoglobin \\\u003C100 g\u002FL\n* Acute illness\n* Respiratory infection or vaccination within 2 weeks prior to surgery\n* Requirement for perioperative intensive care","3 Months",{"count":167,"type":21},[55],"Orofacial clefts are among the most common congenital malformations, affecting approximately 1 in 700-1500 live births worldwide. They are associated not only with aesthetic concerns but also with functional impairments in feeding, speech, hearing, and dentition, and may be accompanied by other systemic malformations, often requiring multiple surgical procedures and long-term multidisciplinary care. Although cognitive development is preserved, the psychosocial impact on both children and families can be significant.\n\nAnesthesia in children with clefts presents specific challenges. Airway management is often more difficult due to anatomical variations, particularly in syndromic patients and those under 1 year of age. Immature organ systems affect drug metabolism, requiring careful dose adjustment. Preoperative anxiety and stress responses are common and may contribute to complications such as laryngospasm and bronchospasm. In the postoperative period, emergence agitation (EA) and emergence delirium (ED) are frequent, with reported incidence up to 80%. These conditions are characterized by restlessness, inconsolability, and disorientation, and may result in self-injury or disruption of surgical repairs.\n\nDifferentiating agitation from pain is challenging in young children due to limited communication abilities. Validated observational tools such as CHIPPS, PAEDS, and Cravero scales are used for routine clinical assessment of pain and EA\u002FED, although their subjective nature may limit accuracy. Therefore, evaluation of the perioperative serum cortisol, alpha-amylase, and neuropeptide Y levels will be used. These biomarkers reflect activation of the physiological stress response and indirectly indicate the presence and intensity of pain.\n\nPain management requires a multimodal approach. While opioids remain standard, their use is associated with adverse effects such as respiratory depression, nausea, vomiting, and delayed recovery. Consequently, opioid-free (OF) strategies using different anesthetics, including ketamine and dexmedetomidine have gained attention.\n\nThis prospective randomized clinical trial will compare opioid-based anesthesia with an opioid-free protocol in children undergoing cleft surgery. A total of 90 patients age of 3 months-7 years will be randomized in a 1:1 ratio. The opioid group will receive fentanyl, while the OF group will receive ketamine and dexmedetomidine; both groups will receive propofol, vecuronium, sevoflurane, and nitrous oxide.\n\nPrimary outcomes are postoperative pain (CHIPPS) and emergence agitation (PAEDS, Cravero). Pain will be assessed at 5 min, 15 min, 1, 2, 12, and 24 h after extubation, whereas emergence agitation will be evaluated at 5 min, 15 min, 1 h, and 2 h post-extubation. While these scales are routinely used in clinical practice, their subjective nature necessitates additional objective assessment. Therefore, secondary outcomes include evaluation of perioperative stress markers (cortisol, alpha-amylase, neuropeptide Y) and adverse events (nausea, vomiting, pruritus, constipation, respiratory depression, altered consciousness) within 24 h. Procedures will be standardized, with morning surgeries to minimize circadian variations of the biomarkers, performed by the same team. Blood samples will be collected before and after intravenous induction.\n\nPostoperative analgesia will include paracetamol and NSAIDs, with fentanyl as rescue therapy.\n\nThe study hypothesis is that opioid-free anesthesia will provide comparable or superior analgesia, reduce the incidence of emergence agitation, attenuate the stress response, and decrease opioid-related adverse effects, thereby improving overall perioperative safety and recovery in pediatric patients undergoing cleft surgery.\n\nThe particular value of this study lies in the subgroup of children who will undergo at least two surgical procedures within the observation period. In these patients, each child will be exposed to both anesthetic protocols in separate procedures-once according to the randomly assigned regimen and the second time according to the alternative protocol. In this way, each patient serves as their own control, allowing for a more precise comparison of outcomes with a substantial reduction in inter-individual variability. This approach largely eliminates individual differences such as age, body weight, baseline hemodynamic status, individual sensitivity to anesthetics and analgesics, as well as variability in stress response and pain perception. Such a design enhances the internal validity of the study and enables a more reliable interpretation of the results.",[387,388,389,390,391,27],"Cleft Lip Palate","Orofacial Cleft","Agitation, Emergence","Analgesia Assessment","Analgesia",[393],"Anesthesia, orofacial clefts, pain control, emergence agitation",{"date":339,"type":35},{"date":396,"type":35},"2024-05-16",{"date":187,"type":21},{"name":399,"class":42},"Iva Smiljanić",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":198,"enrollmentInfo":407,"targetDuration":4,"studyType":22,"phases":409,"briefSummary":410,"conditions":411,"keywords":414,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":420,"leadSponsor":422,"locationsCount":43},"100621384","pediatric-pilonidal-sinus-surgical-treatment-100621384","NCT07369921","Pediatric Pilonidal Sinus Surgical Treatment","Comparison of Four Different Surgical Methods for the Treatment of Sacrococcygeal Pilonidal Sinus: a Randomized Controlled Trial","Inclusion Criteria:\n\n* having sacrococcygeal pilonidal sinus disease\n* written informed (family) consent were eligible for inclusion in this trial\n\nExclusion Criteria:\n\n* Being over 18 years old or under 12 years old\n* recurrent sacrococcygeal pilonidal sinus disease",{"count":408,"type":21},80,[55],"The aim of study to evaluate four different treatment options for pilonidal sinus disease in a randomized controlled trial to find the most suitable treatment option.",[412,413,27],"Surgery","Pilonidal Sinus",[413,415],"pediatric surgery","2026-04-11",{"date":418,"type":35},"2026-04-14",{"date":283,"type":21},{"date":421,"type":21},"2026-05-30",{"name":423,"class":424},"Zeliha Alicikus","OTHER_GOV",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":51,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":457},"100547799","phase-2-a-study-to-evaluate-the-effect-of-aficamten-in-pediatric-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm-100547799","NCT06412666","A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).","A Phase 2\u002F3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy","CEDAR-HCM","Inclusion Criteria:\n\n* Period 1: Treatment Period\n\n  * Males and females between 12 and \\\u003C 18 years of age at screening and at Day 1.\n  * Body weight ≥ 45 kg for the initial cohort and then body weight ≥ 35 kg after at least 10 participants in the initial cohort have undergone dose titration up to Week 4 without observed events of LVEF \\\u003C 50% at the starting dose of 5 mg qd.\n  * Core laboratory confirmation of the following oHCM echocardiographic criteria at screening:\n* Left ventricular (LV) hypertrophy with nondilated LV chamber in the absence of other cardiac disease.\n* LV end-diastolic wall thickness that meets a threshold of:\n\n  * Z-score \\> 2.5 in the absence of family history OR\n  * Z-score \\> 2 in the presence of positive family history or positive genetic test.\n* LVEF ≥ 60% AND Valsalva LVOT-G ≥ 50 mmHg.\n\n  * oHCM of sarcomeric origin confirmed by genetic testing or, if unable to confirm by genetic testing, oHCM of sarcomeric origin may be presumed in the absence of history of metabolic disorders, mitochondrial cardiomyopathies, neuromuscular disease, malformation syndromes, infiltrative diseases\u002Finflammation, and endocrine disorders (such as Fabry's disease, Noonan syndrome with left ventricular hypertrophy, and amyloid-cardiomyopathy).\n  * New York Heart Association (NYHA) Class ≥ II at screening.\n  * Adequate acoustic windows for echocardiography.\n  * Participants on beta blockers, verapamil, diltiazem, or disopyramide should have been on stable doses for more than 4 weeks prior to randomization.\n* Period 2: Open-Label Extension\n\n  * Completed Period 1. If unable to complete Period 1 due to circumstances not related to compliance or safety, the Medical Monitor may review and determine eligibility.\n  * LVEF ≥ 55% after washout.\n* Period 3: Long-term Extension • Completed Period 2.\n\nExclusion Criteria:\n\n* Period 1: Treatment Period\n\nAny of the following criteria will exclude potential participants from the trial:\n\n* Significant valvular heart disease.\n\n  * Moderate or severe valvular aortic stenosis or fixed subaortic obstruction.\n  * Mitral regurgitation that is greater than mild in severity and not due to systolic anterior motion of the mitral valve (per judgment of Principal Investigator or designee).\n  * Evidence of fixed left-sided obstruction (eg, subaortic membrane, aortic valve stenosis, or coarctation of the aorta).\n* History of LV systolic dysfunction (LVEF \\\u003C 45%) or stress cardiomyopathy at any time during their clinical course.\n* History of congenital heart disease other than oHCM (may be enrolled if not hemodynamically significant in the judgement of the Principal Investigator and study Medical Monitor).\n* Has been treated with SRT (surgical myectomy or percutaneous alcohol septal ablation) within the preceding 6 months or has plans for either treatment during the trial period.\n* History of paroxysmal or persistent atrial fibrillation or atrial flutter.\n* History of syncope, symptomatic ventricular arrhythmia, or sustained ventricular tachyarrhythmia within 3 months prior to screening.\n* History or evidence of any other clinically significant disorder, malignancy, active infection, other condition, or disease that, in the opinion of the Principal Investigator (or designee) or the Medical Monitor, would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.\n* Current or previous use of drugs known to cause cardiomyopathy (eg, anthracyclines, monoclonal antibodies \\[trastuzumab\\], alkylating agents \\[cyclophosphamide\\], and tyrosine kinase inhibitors \\[sunitinib and imatinib\\]).\n* Currently participating in another investigational device or drug trial or received an investigational device or drug \\\u003C 1 month (or 5 half-lives for drugs, whichever is longer) prior to screening.\n* Implantable cardioverter defibrillator (ICD) implantation within 6 weeks of screening or planned ICD implantation during the trial period.\n* Has received prior treatment with aficamten or mavacamten.\n* Currently listed for heart transplantation or anticipated to be listed for heart transplantation in the next 12 months.",{"count":434,"type":21},55,[133,436],"PHASE3","The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).",[27,439],"Symptomatic Obstructive Hypertrophic Cardiomyopathy",[441,442,443,439,444,445,431,446],"CK-3773274","CK-274","Aficamten","oHCM","CEDAR","CY 6023","2026-04-08",{"date":449,"type":35},"2026-04-13",{"date":451,"type":35},"2024-05-29",{"date":453,"type":21},"2030-01",{"name":455,"class":456},"Cytokinetics","INDUSTRY",38,{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":465,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":467,"conditions":468,"keywords":473,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":320},"100630136","hem-survive-structuralized-follow-up-for-childhood-hematological-malignancy-survivors-100630136","NCT07483749","HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors","A Multicenter Prospective Study on Structuralized Follow-up Model Construction and Late Effect Burden of Childhood Hematological Malignancy Survivors (HEM-SURVIVE)","Inclusion Criteria:\n\n* Diagnosed with childhood hematological malignancies (ALL, AML, Lymphoma, etc.), Completed primary treatment for ≥12 months.\n* Age 1-21 years.\n* Capable of completing follow-up and data collection.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Severe organ failure preventing follow-up.\n* Major genetic or systemic diseases affecting growth\u002Forgan function.\n* Expected poor compliance or refusal to participate.",{"count":466,"type":21},400,"This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late effects. The study hypothesizes that a standardized follow-up path managed by an electronic platform will improve follow-up compliance and reduce the missed diagnosis rate of late effects.",[469,470,471,472,27],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Lymphoma","Leukemia",[474,475,476,477],"Survivorship","Late Effects","Follow-up Model,","Risk Stratification","2026-03-17",{"date":480,"type":35},"2026-03-19",{"date":482,"type":21},"2026-03-25",{"date":484,"type":21},"2028-12",{"name":486,"class":42},"The Children's Hospital of Zhejiang University School of Medicine",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":16,"minAge":223,"maxAge":494,"enrollmentInfo":495,"targetDuration":497,"studyType":168,"phases":4,"briefSummary":498,"conditions":499,"keywords":502,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":43},"100630041","transcranial-doppler-and-nirs-monitoring-of-cerebral-hemodynamics-in-pediatric-laparoscopic-surgery-100630041","NCT07482514","Transcranial Doppler and NIRS Monitoring of Cerebral Hemodynamics in Pediatric Laparoscopic Surgery","Evaluation of Cerebral Hemodynamic Changes Using Transcranial Doppler and Near-Infrared Spectroscopy During Pediatric Laparoscopic Surgery","Inclusion Criteria: -Children aged 2-10 years\n\n* Scheduled for elective laparoscopic inguinal hernia repair\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Undergoing surgery under general anesthesia\n* Written informed consent obtained from parent or legal guardian\n\nExclusion Criteria:-Known neurological disorders\n\n* Intracranial pathology that may increase intracranial pressure\n* History of cerebrovascular disease\n* Development of intraoperative hemodynamic instability\n* Severe cardiac or respiratory disease\n* Inability to perform transcranial Doppler measurements\n* Parent or legal guardian declines participation","10 Years",{"count":496,"type":21},32,"1 Day","Laparoscopic surgery has become increasingly common in pediatric patients due to its minimally invasive nature and favorable postoperative outcomes. However, the creation of pneumoperitoneum with carbon dioxide (CO₂) insufflation and the use of the Trendelenburg position may increase intra-abdominal pressure and potentially influence intracranial pressure and cerebral hemodynamics. These physiological changes may affect cerebral perfusion and oxygenation during surgery.\n\nThis prospective observational study aims to evaluate cerebral hemodynamic changes during pediatric laparoscopic inguinal hernia repair using transcranial Doppler ultrasonography (TCD) and near-infrared spectroscopy (NIRS). Middle cerebral artery (MCA) flow velocities and pulsatility index (PI) will be measured with TCD as indirect indicators of intracranial pressure, and their relationship with cerebral oxygen saturation measured by NIRS will be assessed. In addition, mean arterial pressure and end-tidal CO₂ values will be recorded to evaluate their association with cerebral hemodynamic changes during different phases of surgery.",[500,501,27],"Cerebral Perfusion Pressure","Trendelenburg",[503,504,505,506,256],"transcranial doppler usg","cerebral perfusion","trendelenburg","nırs","2026-03-15",{"date":480,"type":35},{"date":510,"type":21},"2026-03-16",{"date":512,"type":21},"2027-04-01",{"name":514,"class":42},"Hanife Kabukcu",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":51,"enrollmentInfo":521,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":533,"leadSponsor":535,"locationsCount":537},"100627367","reference-range-study-for-the-quantra-system-with-the-qplus-cartridge-in-pediatric-patients-100627367","NCT07447713","Reference Range Study for the Quantra System With the QPlus Cartridge in Pediatric Patients","Inclusion Criteria:\n\n* Subject is \\\u003C18 years of age\n* Corrected gestational age ≥ 37weeks\n* Subject is scheduled for an elective surgery, non-surgical intervention or diagnostic procedure requiring anesthesia and vascular access with an ASA score ≤3.\n* Subject's parent or guardian has signed an informed consent form. If required, subject has signed an assent form.\n\nExclusion Criteria:\n\n* Subject is hospitalized in the Pediatric Intensive Care Unit\n* Subject requires Extracorporeal Membrane Oxygenation (ECMO)\n* Subject has had an infection within 7 days of the scheduled procedure\n* Subject has an active coagulation disorder (bleeding or thrombosis)\n* For subjects that have a hemoglobin measurement within 24 hours of the scheduled procedure, hemoglobin is \\\u003C8g\u002FdL or \\>16g\u002FdL\n* Subject has a baseline oxygen saturation \\\u003C92%",{"count":522,"type":21},240,"This study will determine reference range intervals for the parameters reported by the Quantra System with the QPlus Cartridge in pediatric patients.",[27,525],"Coagulation",[527,528],"Reference range","Quantra QPlus","2026-02-26",{"date":531,"type":35},"2026-03-03",{"date":262,"type":21},{"date":534,"type":21},"2027-05-30",{"name":536,"class":456},"HemoSonics LLC",4,{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":16,"minAge":545,"maxAge":198,"enrollmentInfo":546,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":43},"100623848","amputations-in-childhood-and-neuropathic-pain-100623848","NCT07401966","Amputations in Childhood and Neuropathic Pain","NAPE","Inclusion Criteria:\n\n* Patients aged between 5 and 18 years (inclusive) (Piaget's concrete operational stage to be able to complete the self-assessment questionnaires)\n* Patients who underwent amputation before the age of 15 for girls and 16 for boys (average age of completion of lower limb growth)\n* Patients who have not undergone surgery on the amputated limb for at least one year (to avoid bias, as any surgery involving incision can cause temporary neuropathic pain unrelated to the amputation)\n* Have obtained the signature of the non-objection form by both parents\u002Flegal guardians\n* Have obtained the child's consent (verbal consent but recorded)\n* Be affiliated with a health insurance plan.\n\nExclusion Criteria:\n\n* Patients who do not speak French\n* Patients whose cognitive abilities are insufficient (as determined by a clinician or reported by parents) to be able to complete self-assessment questionnaires\n* Patients undergoing chemotherapy (due to transient neuropathic pain)\n* Patients who have received chemotherapy and whose side effects have not yet subsided (on a case-by-case basis depending on the chemotherapy used)\n* Patients who have received chemotherapy causing neuropathic pain due to this treatment that has not disappeared.\n* Patients placed under protective custody.","5 Years",{"count":547,"type":21},50,"This observational study aims to assess the presence of neuropathic pain in children and adolescents who underwent limb amputation during childhood.\n\nThe study focuses on two types of neuropathic pain: phantom limb pain and residual limb pain. It also evaluates quality of life and functional autonomy in this population and explores potential associations between neuropathic pain, autonomy, quality of life, and age at amputation.\n\nUsing a mixed retrospective and prospective design, data are collected from medical records and standardized questionnaires administered during routine follow-up visits at a specialized pediatric limb anomaly center. The study seeks to improve understanding of neuropathic pain after pediatric amputation and its impact on daily functioning.",[27,550,551,552],"Neuropathic Pain","Phantom Limb Pain","Amputation","2026-02-20",{"date":555,"type":35},"2026-02-23",{"date":557,"type":35},"2026-02-19",{"date":559,"type":21},"2027-02-02",{"name":561,"class":42},"Hopitaux de Saint-Maurice",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":16,"minAge":568,"maxAge":569,"enrollmentInfo":570,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":577,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":43},"100625884","which-rapid-sequence-induction-technique-should-be-used-in-urgent-surgery-in-children-100625884","NCT07428434","Which Rapid Sequence Induction Technique Should be Used in Urgent Surgery in Children?","Inclusion Criteria:\n\n* children under 14 years of age with a full stomach, scheduled for urgent surgery under general anesthesia\n\nExclusion Criteria:\n\n* hemodynamic instability","1 Month","14 Years",{"count":571,"type":21},100,[55],"The goal of our study is to compare classical Rapid Sequence Induction (RSI) and modified Rapid Sequence Induction (mRSI) in pediatric patients with a full stomach undergoing urgent surgical procedures. Due to reduced oxygen reserve in children, modified RSI incorporating gentle positive pressure ventilation has been proposed to reduce hypoxemia while maintaining protection against aspiration.",[575,576,27],"Rapid Sequence Induction (RSI)","Full Stomach",[578,579,580,581,582],"positive pressure ventilation","aspiration","desaturation","children","urgent surgery","2026-02-16",{"date":555,"type":35},{"date":586,"type":21},"2026-03-01",{"date":588,"type":21},"2026-09",{"name":590,"class":42},"Tunis University",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":16,"minAge":598,"maxAge":599,"enrollmentInfo":600,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":611,"leadSponsor":613,"locationsCount":43},"100622357","natural-course-of-congenital-hydronephrosis-in-infants-aged-0-6-months-100622357","NCT07382570","Natural Course of Congenital Hydronephrosis in Infants Aged 0-6 Months","Multicenter Prospective Cohort Study Protocol on the Natural Course of Congenital Hydronephrosis in Infants Aged 0-6 Months (3-Year Cycle)","Inclusion Criteria:\n\n* Diagnostic Criteria: Congenital hydronephrosis is diagnosed by abdominal ultrasound examination and meets the UTD grading system criteria (Grades I-III). This is defined as an anterior-posterior renal pelvis diameter (APD) ≥4 mm during the fetal period or ≥7 mm after birth, or accompanied by calyceal dilation, renal parenchymal changes, and other manifestations.\n* Informed Consent: The legal guardian voluntarily agrees to participate in the study and provides written informed consent.\n* Follow-up Feasibility: The guardian commits to cooperating with the complete 3-year follow-up period, including attending regular examinations at the research center, and maintains stable contact information.\n\nExclusion Criteria:\n\n* Presence of other severe congenital malformations that may affect follow-up or prognosis assessment, such as congenital heart disease, biliary atresia, spina bifida, etc.\n* Secondary hydronephrosis caused by acquired factors (e.g., urinary system tumors, stones, trauma) or well-defined genetic metabolic diseases.\n* Having received interventional treatments prior to enrollment, such as surgical procedures related to hydronephrosis (e.g., pyeloplasty) or pharmacological interventions (e.g., long-term use of diuretics).\n* Severe underlying diseases that preclude tolerance for long-term follow-up, such as severe infections, respiratory failure, or renal failure (e.g., glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73m²).\n* Inability of the legal guardian to cooperate due to mental illness, cognitive impairment, or refusal to comply with follow-up schedules and data collection requirements.","0 Months","6 Months",{"count":601,"type":21},330,"This project aims to systematically delineate the natural progression of congenital hydronephrosis diagnosed within the critical window of 0-6 months through a prospective, multicenter, observational cohort study. The focus will be on analyzing the resolution rates, progression rates, and influencing factors of hydronephrosis of varying severities based on the UTD grading system.\n\nCongenital hydronephrosis is one of the most common congenital urinary system abnormalities in children, with a high prenatal detection rate. However, its postnatal natural course is highly heterogeneous, leading to significant controversy in clinical management regarding follow-up intensity and intervention timing. Currently, there is a lack of prospective, large-sample, multicenter natural history data in China. By establishing a standardized follow-up system and collecting high-quality clinical and imaging data, this study aims to provide high-level evidence-based medical support for developing individualized and precise clinical management strategies, thereby reducing unnecessary interventions and delayed treatment. Consequently, conducting this multicenter study holds significant clinical and scientific value.",[604,605,606,27],"Congenital Hydronephrosis","UTD Grading System","Natural Progression","2026-02-08",{"date":609,"type":35},"2026-02-11",{"date":586,"type":21},{"date":612,"type":21},"2028-11-30",{"name":486,"class":42},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":16,"minAge":621,"maxAge":80,"enrollmentInfo":622,"targetDuration":4,"studyType":22,"phases":623,"briefSummary":624,"conditions":625,"keywords":628,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":638,"leadSponsor":640,"locationsCount":4},"100621469","the-effect-of-using-distractor-cards-and-thermochromic-cards-on-pain-fear-anxiety-and-procedure-time-in-children-receiving-inhaler-therapy-100621469","NCT07371026","The Effect of Using Distractor Cards and Thermochromic Cards on Pain, Fear, Anxiety and Procedure Time in Children Receiving Inhaler Therapy","CALM-INH","Inclusion Criteria:\n\n* The child must be between 4-6 years old,\n* The child must be receiving inhaler treatment,\n* The child must not have received IV or IM intervention before inhaler treatment,\n* The child's oxygen saturation must be 95% or higher,\n* The child's cognitive level and motor development must be appropriate for their age,\n* The child and parents must be willing to participate in the study,\n* The child and parents must be able to speak Turkish.\n\nExclusion Criteria:\n\n* The child must have a cognitive or mental problem,\n* The child must have special needs in terms of hearing, vision and\u002For speech,\n* The child must have a life-threatening condition,\n* The child's oxygen saturation level must be below 95%,\n* The child must not be routinely receiving inhaler treatment","3 Years",{"count":167,"type":21},[55],"THE EFFECT OF USİNG DİSTRACTOR CARDS AND THERMOCHROMİC CARDS ON PAİN, FEAR, ANXİETY AND PROCEDURE TİME İN CHİLDREN RECEİVİNG INHALER THERAPY.\n\nRespiratory illnesses in children are a leading cause of childhood morbidity and mortality worldwide. Organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) report that millions of children are hospitalized each year due to respiratory illnesses (He, Wang, \\& Zhang, 2025). A large proportion of these illnesses are caused by viral agents, and pathogens such as Respiratory Syncytial Virus (RSV), influenza, and rhinoviruses pose serious health threats to young children (Chen, Zhang, \\& Li, 2024).\n\nThis study will be one of the rare studies in pediatric nursing that examines the effectiveness of non-pharmacological interventions that can be applied during inhaler therapy in young age groups. The findings will contribute to nurses developing effective methods to reduce the negative emotions experienced by children during treatment. Furthermore, the first-ever use of thermochromic cards in this context in pediatric nursing will provide an innovative perspective on pediatric nursing practices.\n\nH0: Thermochromic cards and distraction cards used during inhaler therapy have no effect on pain, fear, anxiety levels, or processing time.\n\nThermochromic cards used during inhaler therapy:\n\nH1: reduce the child's pain. H2: reduce the child's fear. H3: reduce the child's anxiety level.\n\nH4: shorten the child's processing time. Distraction cards used during inhaler therapy:\n\nH5: reduce the child's pain. H6: reduce the child's fear. H7: reduce the child's anxiety level. H8: shorten the child's processing time.",[626,27,627],"Pediatric Acute Upper Respiratory Tract Infection","Pediatric Acute Respiratory Failure",[629,630,631,632,633],"pediatrics","nebulizer therapy","thermochromic card","child","distracting card","2026-01-28",{"date":636,"type":35},"2026-01-30",{"date":586,"type":21},{"date":639,"type":21},"2027-03-01",{"name":641,"class":42},"Muhammed Ata Nur GEÇER",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":4,"eligibilityCriteria":648,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":198,"enrollmentInfo":649,"targetDuration":4,"studyType":22,"phases":650,"briefSummary":651,"conditions":652,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":43},"100424777","tranexamic-acid-in-pediatric-undergoing-proximal-femoral-osteotomies-andor-acetabular-osteotomy-100424777","NCT04811313","Tranexamic Acid in Pediatric Undergoing Proximal Femoral Osteotomies and\u002For Acetabular Osteotomy","Impact of Tranexamic Acid Use on Blood Loss and Transfusion Rates After Hip Reconstruction in Children, A Randomized Controlled Trial","Inclusion Criteria:\n\n* ASA I - II\n* Scheduled for acetabular osteotomy and\u002For proximal femoral derotation osteotomies.\n\nExclusion Criteria:\n\n* Patient's guardian refusal to participate in the study.\n* Children known to have pre-existing bleeding or coagulation disorders.\n* Children with anemia; defined according to (WHO ) cutoffs as Hb level\\\u003C11g\u002Fdl for girls and \\\u003C12g\u002Fdl for boys\n* History of epilepsy.\n* History of renal insufficiency or failure",{"count":466,"type":21},[55],"Surgical hip reconstruction reduces the hip joint through soft tissue releases and osteotomies of the femur and\u002For pelvis. Blood loss and subsequent blood transfusion are normal consequences of hip reconstruction.",[653,27,654],"Intraoperative Blood Loss","Orthopedic Disorder",{"date":656,"type":35},"2025-11-17",{"date":658,"type":35},"2025-04-03",{"date":660,"type":21},"2026-03",{"name":239,"class":42},{"id":663,"slug":664,"hasResults":12,"nctId":665,"briefTitle":666,"officialTitle":667,"acronym":4,"eligibilityCriteria":668,"healthyVolunteers":12,"sex":16,"minAge":246,"maxAge":51,"enrollmentInfo":669,"targetDuration":4,"studyType":22,"phases":671,"briefSummary":672,"conditions":673,"keywords":675,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":686,"leadSponsor":688,"locationsCount":43},"100609932","impact-of-facility-dog-intervention-on-pediatric-patients-100609932","NCT07221006","Impact of Facility Dog Intervention on Pediatric Patients","Investigating the Impact of Facility Dog Intervention on Pediatric Patient Fear, Coping, and Anxiety During Inpatient Admission","Inclusion Criteria:\n\n* Children admitted to an inpatient unit at Children's Hospital Colorado Anschutz Medical Campus\n* Who are eight to 17 years old.\n\nExclusion Criteria:\n\n* Isolation precautions\n* Primary reason for admission is due to suicidality, self-injurious behavior, or injurious behavior\n* Patients with history of or currently presenting with aggression or unsafe behavior\n* Severe comorbidities secondary to traumatic brain injury, neurological disorder or neurodevelopmental issues that may confound study outcomes and administration of the study protocol (e.g., intellectual disability)\n* Not medically stable\n* Have a fear of dogs\n* Have an allergy to dogs\n* Have had a visit from a medical dog and medical dog handler during their current admission\n* Patient has an urgent or time-sensitive need requiring medical dog support - Patient is non-verbal.",{"count":670,"type":21},126,[55],"The goal of this clinical trial is to learn if medical dog intervention facilitated by a Certified Child Life Specialist (CCLS) impacts pediatric patient coping, fear, and anxiety during inpatient admissions. The main questions it aims to answer are:\n\nWhat impact does facility dog support via a CCLS have on patient fear, coping, and anxiety? What effect does facility dog support via a CCLS have on patient heart rate? Researchers will compare medical dog intervention facilitated by a CCLS, CCLS intervention, and a coloring activity to see if medical dog interventions positively impact coping, fear, and anxiety.\n\nParticipants will:\n\nReceive a visit from a medical dog and their CCLS handler, a CCLS, or a Child Life Activity coordinator.\n\nEngage in a mindfulness or coloring activity. Answer surveys regarding anxiety, coping, and fear. Have their heart rate measured before, during, and after their assigned intervention.",[674,27],"Inpatients",[676,677,678,679,680],"Emotional Support Dog","Pet Therapy Dog","Child Life Specialist","anxiety","fear","2025-10-31",{"date":683,"type":35},"2025-11-03",{"date":685,"type":21},"2025-12-01",{"date":687,"type":21},"2026-12-01",{"name":689,"class":42},"Children's Hospital Colorado"]